v1.6 06 December 2021

| Short project title*: | / Improvement Programme (PQIP) | | | | | | | | | | |
|---|--------------------------------|-----------------------------|-----------|--------------|----------------------|--|--|--|--|--|--|
| IRAS project ID* (or REC reference if no IRAS project ID is available): | 215928 | | | | | | | | | | |
| Sponsor amendment reference number*: | Non-Substantial Amer | ndment 27 | | | | | | | | | |
| Sponsor amendment date* (enter as DD/MM/YY): | 28 November 2023 | | | | | | | | | | |
| Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*: | Addition of New Site PI. | | | | | | | | | | |
| | | | | Specific stu | dy | | | | | | |
| Project type (select): | | | | Research tis | Research tissue bank | | | | | | |
| | | | | Research da | Research database | | | | | | |
| Has the study been reviewed by a UKECA-recognised Rese Committee (REC) prior to this amendment?: | Ye | ·s | No | | | | | | | | |
| | | | | NHS/HSC REC | | | | | | | |
| What type of UKECA-recognised Research Ethics Committee is applicable? (select): | ee (REC) review | Ministry of Defence (MoDREC | | | | | | | | | |
| Is all or part of this amendment being resubmitted to the Res Committee (REC) as a modified amendment (i.e. a substa previously given an unfavourable opinion)? | Υe | es | No | | | | | | | | |
| Where is the NHS/HSC Research Ethics Committee (REC) | that reviewed the | England | Wales | Scotland | Northern Irela | | | | | | |
| study based?: | | Yes | No | No | No | | | | | | |
| Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: | product (CTIMP) | Ye | es. | 1 | No | | | | | | |
| Was the study a clinical investigation or other study of a medoes the amendment make it one?: | dical device OR | Ye | es . | No | | | | | | | |
| Did the study involve the administration of radioactive substrequiring ARSAC review, OR does the amendment introduce | | Ye | es . | | No | | | | | | |
| Did the study involve the use of research exposures to ionisi involving the administration of radioactive substances) OR damendment introduce this?: | Ye | es | No | | | | | | | | |
| Did the study involve adults lacking capacity OR does the arintroduce this?: | Ye | es . | No | | | | | | | | |
| Did the study involve access to confidential patient informati direct care team without consent OR does the amendment in | Ye | es | No | | | | | | | | |
| Did the study involve prisoners or young offenders who are is supervised by the probation service OR does the amendment | Ye | es | No | | | | | | | | |
| Did the study involve children OR does the amendment intro | Ye | es | No | | | | | | | | |
| Did the study involve NHS/HSC organisations prior to this at | Ye | s | No | | | | | | | | |
| | the amendment | Υe | es . | No | | | | | | | |
| Did the study involve non-NHS/HSC organisations OR does introduce them?: | | | Wales | Scotland | Northern Irela | | | | | | |
| | | England | | | | | | | | | |
| | | England Yes | No | No | No | | | | | | |
| introduce them?: | or to this | Ü | No Yes | No Yes | No Yes | | | | | | |

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

| Change 1 | | | | | | | | | |
|---|---|-------|----------|------------------|------------|--|--|--|--|
| Area of change (select)*: | Researchers | | | | | | | | |
| Specific change (select - only available when area of change is selected first)*: | PI - New PI, or temporary arrangements to cover the absence of a PI | | | | | | | | |
| Further information (free text - note that this field will adapt to the amount of text entered): | New PI's: Henry Lewith - Kingston Hospital NHS Foundation Trust. | | | | | | | | |
| Applicability: | England | Wales | Scotland | Northern Ireland | | | | | |
| Where are the participating NHS/HSC organisations located this change?*: | that will be affected by | Yes | Yes | Yes Yes | | | | | |
| Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the category | • • • | A | di . | Some | | | | | |
| | | | | Add anot | her change | | | | |

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

| Name [first name and surname]*: | Pushpsen Joshi |
|---------------------------------|-------------------------|
| Email address*: | pushosen.joshi1@nhs.net |

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

| | Review bodies | | | | | | | | | | | | | | | | | | |
|----------------------------------|--|---|---------------------------------------|--------------------|---------------------|-----------------|-----------|-----|-------|-----------------------|-------------------|------|------------|--------------------------------|---------|--------------------|---------|--------------------------------|-----------|
| | UK wide: | | | England and Wales: | | | Scotland: | | | | Northern Ireland: | | | | | | | | |
| | REC | Competent Authority MHRA - Medicines | Competent Authority MHRA - Devices | ARSAC | Radiation Assurance | UKSW Governance | REC (MCA) | CAG | HMPPS | HRA and HCRW Approval | REC (AWIA) | PBPP | SPS (RAEC) | National coordinating function | HSC REC | HSC Data Guardians | Prisons | National coordinating function | Category: |
| Change 1: | | | | | | (Y) | | | | (Y) | | | | (Y) | | | | (Y) | Α |
| Overall reviews for the amendmen | nt: | | | | | | | | | | | | | | | | | | |
| Full review: | | | | | | N | | | | N | | | | N | | | | Ν | |
| Notification only: | | | | | | Υ | | | | Υ | | | | Υ | | | | Υ | |
| Overall amendment type: | Non-substantial, no study-wide review required | | | | | | | | | | | | | | | | | | |
| Overall Category: | Α | | | | | | | | | | | | | | | | | | |